Author Queries€¦ · Web viewUse these as far as possible for your queries, but you may need to...

Last updated 22 May 2020

AUTHOR QUERIES FOR COPY-EDITORS

Use these as far as possible for your queries, but you may need to adapt them to suit the particular paper and to make them more specific. It’s especially useful to provide specific examples of the styling of genes or proteins mentioned in the paper.

Please make your queries as succinct and specific as possible to reduce the number/length of queries.

Ctrl + click on any of the following topics to take you straight to the query:

TITLEModification of title (general)Modification of title (animal)

AFFILIATIONSAuthor names AffiliationAffiliations (order)Two corresponding authorsStudy GroupStudy Group on PubMedCIBERDEM and CIBERESPDZDSingapore in affiliationsHong Kong in affiliationsParticles

RESEARCH IN CONTEXT AND TWITTERResearch in contextTwitter

ABBREVIATIONSAbbreviations (standard)Abbreviations (written-out)Abbreviations (gene symbols)

THROUGHOUT TEXTStyle changesSubjects vs participantsPatientsCaucasiansTriglyceride/triacylglycerolFree fatty acids/NEFAHDL/LDLGender/Sex

Male/FemaleLatin termsWt or vol.High-/low-calorie and isocaloricParameters/variablesWebsitesAntidiabetic drugsMortality rate/riskPrediabetesDiabetic footUtiliseOptical densityALT/ASTVitreousSaline

ETHICS PERMISSIONEthics permission (animals)Ethics permission (humans)Ethics permission (organ donors)Ethics permission (donated human cells)Ethics permission (database studies)

SOURCE DETAILSAddress (animals)Address (chemicals/equipment)Address (software)Trademarks and company typeResource identifiers

UNITSSI unitsReporting of HbA1c unitsUnits for area under the curve (AUC)HOMA equation

of 53


MINMOD program (insulin sensitivity)Molecular weight/massNormal (N) values for solutionsUnits (U)/International Units (IU)

PRECLINICAL STUDIESReplicatesData expressionStatisticsRandomisationBlindingExclusionAnimal strainAntibodies

GENES/PROTEINSStyling: genes vs proteinsStyling: human vs rat/mouseStyling: mRNAStyling: western blotsStyling: northern blotsStyling: knockdown studiesExpressed vs produced (general)Expressed vs produced (cell surface markers)Expressed vs produced (mRNA)Old vs up-to-date symbol (human)Keywords: Add old and up-to-date symbolsHLA allele formatHLA gene family stylingGene set analysesPCR primers

STATISTICSStatistics: r values Data expressionStatistical testsTrendβ Coefficients Interquartile rangeAverage

RANDOMISED CONTROLLED TRIALS

CONSORT guidelines: abstract

CONSORT guidelines: flow diagram

Trials mentioned in other types of article

MISCELLANEOUSUnpublished observations/results/dataPersonal communicationAnimal models of diabetesMatchingLogarithmsLogarithms (ln)ExponentsICD-9 and -10Read codesDrug namesSacrificed vs killedAbstracts in commentariesData in the abstractqRT-PCR

END MATTERAcknowledgementsFundingFunding by UK research councilsFunding by the Wellcome TrustSpringer CompactContribution statementGuarantorAuthors’ relationships and activitiesResearch data

of 53


REFERENCESConverting EndNote to plain textAuthor name/reference mismatchAbstract out-of-dateReference in preparation/submittedIn pressAccepted for publicationePub ahead of printWebsitesCochrane reviews

FIGURESFigure part labellingDeletion of legendDeletion of p values Figures not cited in rising orderExplanation of statistical symbolsChange of statistical symbolsp values Logarithmic and irregular scale s High-resolution figuresForest plots

Individual data pointsy -axis values n values Scale barsDownloadable slidesets

MULTIMEDIA MANUSCRIPTS

TABLESTables not cited in rising orderFormatting (gridlines)Formatting (rows of space)Formatting (bold type)Formatting changesLarge tables

ESM

COMMENTS (LETTERS)Comment titleReply to comment, title

REVIEWSSubheadingsFigures to illustratorPermissionsText box

of 53


TITLE

Modification of title (general)

The title has been modified slightly in line with journal style [details]. Please use the amended title if you refer to this paper elsewhere, or if you use the title in any electronic supplementary material.

We would like to suggest [details] as our press officer has suggested that shorter titles can have a greater impact.

Modification of title (animal)

The animal species has been added to the title in line with journal policy. Please use the amended title if you refer to this paper elsewhere, or if you use the title in any electronic supplementary material.

<Back to index>

of 53


AFFILIATIONS

Author names

Diabetologia style is to include given (first) name, initials and family name in the author list, e.g. John M. Smith, Yu-fei Shan, Soo Heon Kim, J. Edgar Hoover. Please ask your co-authors to amend their names in line with this, as appropriate.

[Copyeditors and proofreaders please note that Korean given names are often unhyphenated two-part names such as Soo Heon, Sung Hee; similarly Italian names often have unhyphenated two-part first names, such as Gian Paolo; in such cases both names should be retained in the author list. Please check with the Editorial Office or raise an author query if you are unsure.] Please could you confirm whether [X] is a middle name that should be abbreviated to the initial, or whether it is part of a two-part first name or two-part family name? We will then ensure it is coded correctly in the metadata and should appear correctly on PubMed.

Affiliation

In line with journal style, affiliation XXX has been replaced with the address for correspondence (in the PDF version it will appear only once, as an affiliation).

Please check that this address applies to all authors listed as having this affiliation and modify if necessary.

OR

In line with journal style, affiliation XXX has been amended to include the full address for correspondence (in the PDF version it will appear only once, as an affiliation).

Please check that this address applies to all authors listed as having this affiliation and modify if necessary.

Affiliation (more than one)

Different affiliations, including different departments within the same institution (but not joint departments/organisations) should be listed separately.

Should affiliation [?] therefore be rewritten as …?

Affiliation (postal details)

Full postal details are only needed for the address of the corresponding author, and have been deleted from other affiliations.

Affiliations (order)

The publisher requires that affiliations should be given in the order: department/division, institution/organisation, town/city, country. Please amend affiliation XXX in line with this.

of 53


Affiliations (ask co-authors to check all affiliations have been included)

Please check with your co-authors that they have included all their affiliations, as it is difficult to add additional affiliations at the proof stage.

Affiliations (corporate affiliation moved from footnotes/acknowledgements)In order to include full affiliation details for each author, we do not include affiliation details as footnotes or acknowledgements. Therefore the details of (COMPANY NAME) have been added as an additional affiliation. Please check with your co-author that this is acceptable. Please note that this change might need to be checked and approved by the compliance team of the company in question; let us know if this change contravenes compliance guidelines.

Two corresponding authors

The copyright link and proofs are sent by automated process to one author only. Which of the two corresponding authors would you like to nominate to receive these?

[Ed Office only]: Corresponding author/ScholarOne mismatch [NB consider open access eligibility first – CTS may need to go to corresponding author to qualify for Springer Compact]

The copyright link and proofs are sent by automated process to one author only. Should they be sent to [X] (corresponding author on the paper) or [Y] (contact author on ScholarOne)?

Study Group

Please check with your co-authors and/or trial co-ordinators to ensure that any guidelines for the representation of the Study Group in the title, author list and affiliations are followed.

For more information, see the NLM Fact Sheet Authorship in MEDLINE at www.nlm.nih.gov/pubs/factsheets/authorship.html.

Study Group members on PubMed (applies if study group is sole author or listed as author [‘and’]; may also apply for ‘on behalf of’ but this is less clear)

If you wish the study group members to be listed as collaborators on PubMed, please include full affiliation details of study group members, with details of institution, city, state (USA, Canada and Australia) and country.

You include XXX Study Group in the author list and in the [footnotes/acknowledgements/appendix/ESM] you have identified people as authors or as members of the writing group/writing committee for this study group. They will therefore be added as authors on MEDLINE/PubMed (and will be appear after any authors listed in the main author list on the paper). For more information, see the NLM Fact Sheet Authorship in MEDLINE at www.nlm.nih.gov/pubs/factsheets/authorship.html.

of 53

http://www.nlm.nih.gov/pubs/factsheets/authorship.html

http://www.nlm.nih.gov/pubs/factsheets/authorship.html


Please include full affiliation details of study group authors/members of the writing group, with details of department, institution, city, state (USA, Canada and Australia) and country.

Move study group list to ESM (only if very long/Ed Office to raise this query of needed)

Please remove all lists of names (Program Office; Clinical Coordinating Center: Clinical Centers etc) from the manuscript and instead allow us to publish them as electronic supplementary material (ESM) on our website. Please supply the lists in a separate Word document and insert a reference to the electronic supplementary material at relevant places in the text.

CIBERDEM, CIBERESP etc.

Please confirm that we can insert the URL for the umbrella organisation CIBERDEM, as an alternative to the physical address:

Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spainwww.ciberdem.org/

Please confirm that we can insert the URL for the umbrella organisation CIBERDEM, as an alternative to the physical address:

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spainwww.ciberesp.es/

[Copy-editors: if full location details are given by the author, e.g. ‘Instituto de Salud Carlos III (ISCIII), Madrid, Spain’, there is no need to add the URL as well.]

German Center for Diabetes Research (DZD)

The DZD affiliation has been amended in line with instructions received from the DZD on standard layout.

Singapore in affiliations

We are required to provide both city and country for affiliations. ‘Republic of Singapore’ has therefore been inserted after ‘Singapore’.

Particles in author names (de, de la, von, van, del, etc.)

Author name: XXX

of 53


It is important that you check with your co-author exactly how they would like their name to appear in the author list (this will determine how it appears in PubMed).

[Insert specific example]For example:

Jane von Braun: appear as ‘von Braun, J, ‘Von Braun, J’ or ‘Braun, JV’ or ‘Braun, J’?

In particular, please confirm lower or uppercase for von/Von.

<Back to index>

RESEARCH IN CONTEXT & TWITTER

Research in context: GeneralThank you for supplying text for a Research in context box. We have carried out a light edit, and it will be formatted using our standard template before typesetting.

Add if word count is >230 words Please reduce the length of your ‘Research in context’ summary to <200 words (excluding our questions).

Research in context: [add if needs reformatting – or adapt as required if only some sections need to be re-written]Please revise your ‘Research in context’ summary to include the following questions and your responses in bullet point format:What is already known about this subject? (maximum of 3 bullet points)What is the key question? (one bullet point only; formatted as a question)What are the new findings? (maximum of 3 bullet points)How might this impact on clinical practice in the foreseeable future? (one bullet point only)

Please re-phrase point 2 (What is the key question?) in the form of a question.

TwitterThank you for supplying a tweet to accompany your paper. It has been passed to our social media coordinator to use when your article is published.

We will include an image with the tweet, where possible. Please identify which figure/figure part or table would be most effective, or whether you would prefer to use the research in context box or a screenshot of the title and author list.

We are committed to making your research as widely accessible as possible and will tweet about accepted papers (https://twitter.com/DiabetologiaJnl). Please include a tweet and any hashtags or handles (maximum of 250 characters, including spaces and handles) on the title page of your article. Your tweet can be based on the title of your paper or the main finding(s). (s).

of 53

https://twitter.com/DiabetologiaJnl


We will include an image with the tweet, where possible. Please identify which figure/figure part or table would be most effective, or whether you would prefer to use the research in context box or a screenshot of the title and author list.

[copy-editor, please note that if the paper contains a graphical abstract, this will be used with the tweet and so instead of asking which image to use, include the following option]We will include your graphical abstract with the tweet.

ABBREVIATIONS

Abbreviations (standard)

XXX is a standard abbreviation (see http://diabetologia-journal.org/about-the-journal/diabetologia-style-guide/accepted-abbreviations/) that can be used without definition. Your paper has been amended accordingly

Standard abbreviations, such as [XXX], can be used without definition (see http://diabetologia-journal.org/about-the-journal/diabetologia-style-guide/accepted-abbreviations/). Your paper has been amended accordingly.

If used more than once, the abbreviation has been added to the abbreviations list.

Please note that abbreviations used only once in the paper will not be included in the abbreviations list.

The following abbreviations have been written in full throughout, to ensure readability: XXX. These abbreviations have been used and defined separately in the figures and tables where necessary for space reasons.

In line with journal style, the following abbreviations have been written in full throughout: XXX. These abbreviations have been used and defined separately in the figures and tables where necessary for space reasons.

[NB copy-editors – we generally avoid short abbreviations for diseases and conditions (see style guide) and may otherwise write abbreviations in full to improve readability, particularly if the abbreviation is used inconsistently or sparsely. However, there are several short abbreviations (such as MR, DI) that are widely used, so we do not have a rule of disallowing two-letter abbreviations in general. If you are unsure (e.g. a new abbreviation you haven’t encountered before) please check with the Editorial Office before making changes, or add it to the checklist as a query and we can make the change if we think it is appropriate.]

Abbreviations (written-out)

Please give written-out versions of:XXX

Abbreviations (gene symbols)

of 53


Gene symbols are not, strictly speaking, abbreviations and so have been deleted from the abbreviations list.[List here]

of 53


<Back to index>THROUGHOUT TEXT

Style changes

A number of standard journal style changes have been made to the document, for example the use of UK spelling, standard abbreviations etc. These changes have not been tracked. This will make it easier for you to see the more important changes to the text, which are tracked. Further details of the standard changes can be found here. Please do not reverse any of these style changes but instead let us know if you have any queries.

Subjects vs participants

To make it clear to readers that participation in the study was voluntary, Diabetologia prefers that ‘subject’ is replaced by another term such as ‘participant’, ‘individual’ or ‘volunteer’. This change has been made for you throughout. (An exception is made for people who are studied by use of a database where permission is not sought from each individual.)

Patients

The text has been modified as we prefer to avoid unnecessary use of the term ‘patient’ (‘patient’ can be used when discussing a person in terms of their treatment, but ‘participant’ or ‘individual’ is more appropriate when discussing study participation). [Note for copy-editors: in some instances ‘patient’ is preferred where the terminology is standard, e.g. ‘patient-reported outcomes’, ‘patient-centred care’.]

Cases

Changes have been made to avoid use of term ‘case’ to describe a person, when another term, such as ‘individual’ or ‘participant’, would be more appropriate.

Caucasians

In line with AMA recommendations (AMA Manual of Style, 10th edn, ch 11.10.2 Race/Ethnicity, p. 415), Diabetologia does not use the term ‘Caucasian’, which is considered to be non-specific and inaccurate. The term ‘white’ is a suitable alternative: this change has been made for you throughout (‘Europid’ or ‘of European descent’ are also acceptable terms).

Triglyceride/triacylglycerol

In line with IUPAC recommendations (https://old.iupac.org/publications/books/principles/principles_of_nomenclature.pdf), ‘triglyceride’ has been changed to ‘triacylglycerol’ throughout the paper.

[Note that the exception to this is the enzyme ‘adipose triglyceride lipase’, which should not be changed to ‘adipose triacylglycerol lipase’.]

<Back to index>

of 53

http://diabetologia-journal.org/wp-content/uploads/2019/02/Untracked-style-changes.pdf


Free fatty acids/NEFA

In line with IUPAC recommendations (https://old.iupac.org/publications/books/principles/principles_of_nomenclature.pdf), ‘free fatty acid’ has been replaced by ‘NEFA’ (non-esterified fatty acid)

HDL/LDL

Where you use the terms ‘HDL’ and ‘LDL’ are you referring to HDL-cholesterol and LDL-cholesterol, respectively? Please change where appropriate.

Gender/sex

‘Gender’ (cultural term) has been replace by ‘sex’ (biological term) throughout.

Males/females

Males/females used as nouns have been replaced with men/women (male/female are generally used as adjectives when referring to people).

Latin terms

In line with journal style, Latin terms that appear in the Oxford English Dictionary, e.g. in vitro, will be formatted in upright type, not italics.

<Back to index>

Wt or vol.

Please specify whether % concentrations are by weight or by volume (e.g. wt/vol., wt/wt, etc.):[e.g. Provide a single example here]

High-/low-calorie and isocaloric

‘Calorie’ has been changed to ‘energy’ throughout, as calorie is a (non-SI) unit, whereas energy is the thing being measured.

[Note that the term VLCD, very low calorie diet, is allowed because it is widely used in the literature. It should be described as a ‘diet very low in energy (very low calorie diet

of 53


[VLCD])’ at first mention.In addition, ‘caloric restriction’ can be used as it is a scientific term referring to a feeding regimen]

‘Isocaloric’ has been replaced by ‘isoenergetic’ throughout (calorie is a [non-SI] unit, whereas energy is the thing being measured).

Parameters/variables

‘Parameter’ is used for an arbitrary constant within an experiment or mathematical term, whereas ‘variable’ is used for an expression that can be assigned any of a set of values. In line with this standard English usage, parameters has been replaced by variables where appropriate.

Websites

Please give the date that the site was accessed (day/month/year).

Antidiabetic drugs

In line with journal policy, ‘antidiabetic’ drugs has been replaced by ‘glucose-lowering’ drugs.

Mortality rate/risk

Would it be appropriate to change ‘mortality’ to ‘mortality rate’ and/or ‘mortality risk’ to improve clarity? Please check the use of the term ‘mortality’ throughout and amend, as appropriate. [Copy-editors: Please note that ‘all-cause mortality’ is a term that is widely used and understood, so query does not need to be added for this usage]

of 53


Prediabetes: type 2

Diabetologia prefers to avoid the terms ‘prediabetes’ and ‘prediabetic’ except in a purely temporal sense. As prediabetes does not have an accepted definition, please replace with, for example, ‘impaired glucose tolerance’ and/or ‘impaired fasting glucose’.

Prediabetes: type 1

Diabetologia prefers to avoid the terms ‘prediabetes’ and ‘prediabetic’ except in a purely temporal sense. As prediabetic does not have an accepted definition, please replace with, for example, ‘at risk of diabetes’ or ‘with diabetes-related autoantibodies’.

[NB: copy-editors – if this term is used throughout the paper, it is OK to define it at first mention, or at the most appropriate point in the Methods, and then continue to use it. Please tweak the query accordingly. If authors have already included a clear definition of prediabetes, there is no need to raise a query at all].

Diabetic foot

Diabetologia prefers to avoid the term ‘diabetic foot’, where possible. Please replace with a more precise term, such as ‘osteomyelitis of the foot in diabetes’ or ‘soft-tissue foot infection in diabetes’. Where the term occurs throughout the paper, it can be retained, but must be clearly defined at an appropriate place in the text.

Utilise

Strictly speaking, ‘utilise’ means to make the best use of something not intended for the job. Instances of ‘utilise’ have been changed to ‘use’ throughout.

Optical density

The Oxford Dictionary of Biochemistry and Molecular Biology no longer recommends the use of ‘optical density’ as an alternative for ‘absorbance’. Can OD450 and OD690 be changed to absorbance at 450 and 690 nm respectively? [change these wavelengths as appropriate]

ALT and AST

Alanine transaminase has been changed to alanine aminotransferase in line with AMA recommendations and journal style.

Aspartate transaminase has been changed to aspartate aminotransferase in line with AMA recommendations and journal style. [Combine as appropriate]

Vitreous

Where ‘vitreous’ is used as a noun, can it be replaced by ‘vitreous’ body or ‘vitreous humour’?

of 53


Saline

‘154 mmol/l NaCl’ has been added where you first mention saline. Please amend if this is incorrect.

<Back to index>

of 53


ETHICS PERMISSION

Ethics permission (animals)

Please insert a sentence confirming that experiments involving animals were approved by the local ethics committee or that the study was conducted in accordance with the Guide for the care and use of laboratory animals (2011) (http://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf)

Ethics permission (humans)

Please insert a sentence confirming: (1) that study participants gave informed consent; and (2) that your investigations have been approved by the responsible ethics committee (institutional review board) and/or were carried out in accordance with the Declaration of Helsinki as revised in 2008 (www.wma.net/en/30publications/10policies/b3/index.html).

Assent for children (add for studies in children, where formal consent has been obtained from parents/carers)

Please confirm whether assent was sought and obtained from the children involved in this study.

Ethics permission (organ donors/autopsy samples)

Organ donors: please insert a sentence confirming that your investigations have been approved by the responsible ethics committee (institutional review board).

Autopsy samples: please insert a sentence confirming that your investigations have been approved by the responsible ethics committee (institutional review board).

Donated human cells: please insert a sentence confirming that your investigations have been

approved by the responsible ethics committee (institutional review board).

Ethics permission (database studies)

Please insert a sentence confirming that the study has the approval of the local ethics committee and/or health authority from which the data were obtained.[Not needed for publically available gene databases such as MAGIC, DIAGRAM, GIANT, GLGC, ICBP, ADIPOgen, or if the data are anonymised, i.e. individual patients cannot be identified, but if in doubt, raise an AQ or ask the Editorial Office.]

OR (for routinely-collected clinical data):Please insert a sentence stating that the ‘owner’ of the routinely collected data (e.g. Caldicott guardians of the Trusts) has given permission for publication.

of 53

http://www.wma.net/en/30publications/10policies/b3/index.html


<Back to index>

of 53


SOURCE DETAILS

Address (animals)

Please give the source (supplier’s name and country), species, strain, international strain nomenclature, sex, genetic background and age of animals as well as details of housing and husbandry. [Provide examples here]

Address (chemicals/equipment)

Please give the name and country of the following manufacturers/suppliers on first mention.[Provide examples here]

Address (software)

Please give details of software in one of the following formats: (1) the URL from which the software was downloaded, or at which the software can be used; (2) the name and location (country) of the supplier; (3) for some types of software, a reference can be added, included in the main reference list: e.g. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria

For all software, please also include either the version number or the date of access for the website (day/month/year).

Trademarks and company type

In line with journal style, trademarks (e.g. TM, ®) and company type (e.g. Inc., GmbH) have been deleted from supplier details in your manuscript.

Resource identifiers

Please ensure you have provided Research Resource Identifiers (RRIDs) and/or unique identifiers (catalogue numbers etc.) for any key resources used in this study, such as transgenic animals, genetic tools, antibodies etc. Please see https://scicrunch.org/resources for more details of RIIDs.

<Back to index>

of 53

https://scicrunch.org/resources


UNITS

SI units

Diabetologia uses SI units throughout. For an SI conversion table see AMA Manual of Style: SI Conversion Table

NB An exception is made for: - Administered doses of insulin, which can be given in U - Plasma/serum glucagon, which can be given in pmol/l- Serum enzymes (e.g. ALT), which can be given as U/l- CRP, which can be reported either as μg/l or nmol/l

Please convert values for XXX into SI units.[give specific variables/units/location(s)]

Please convert values for plasma glucose to SI units (mmol/l).

Please convert values for plasma insulin to SI units (pmol/l).

Please convert values for plasma amino acids to SI units (mmol/l).

Please convert units for NEFA to SI units (mmol/l) [can also be given as mEq/l]

Please convert units for radioactivity in Ci to SI units (Bq).

Please convert values for ACR in mg/g to SI units (mg/mmol).

Please convert values for centrifuge speed in rpm to g.

Please convert units for energy in kcal to SI units (kJ or MJ). If you wish, you may give values in non-SI units (kcal) in parentheses. Please use the conversion factor 1 kcal = 4.184 kJ.

Please re-draw Fig. 000 to show XXX in SI units (XXX) and send it to us directly by email.

<Back to index>

Reporting of HbA1c units

Please present results for HbA1c in mmol/mol with percentage units in parentheses, e.g. HbA1c

level was 31 mmol/mol (5.0%), in your paper and ESM.

[For figures with values in %]Please present results for HbA1c in mmol/mol in figures

[For tables, please add the following]

of 53

http://www.amamanualofstyle.com/oso/public/jama/si_conversion_table.html


Please include HbA1c values expressed in mmol/mol in a separate row above the % values.

[Copy-editors please note: we relax this rule when the author is reporting data from another paper, e.g. in a review or the discussion. In this instance, HbA1c should still be dual reported but % can come before mmol/mol if this was how the original paper reported the values]

Units for area under the curve (AUC)

The units for area under the curve (AUC) should be in the format y-axis unit × x-axis unit (e.g. for glucose level vs time, the unit would be mmol/l × min). Please check your units to ensure that they are correct.

<Back to index>

HOMA equation

We cannot accept the HOMA equation written-out with non-SI units. If you would like to provide an equation, it should include SI units (glucose in mmol/l, insulin in pmol/l). Please bear in mind that the constant will also be altered (note that the constant varies depending on the standardisation of your insulin assay and its cross-reactivity with proinsulin species).

Important: It is not necessary to recalculate the HOMA values, as equations with non-SI units generate the same values as equations with SI units (which is why they have different constants), provided that values in the units specified in the particular equation are used.

Alternatively, you may omit the equation and provide a reference. In this case, you may need to re-number the subsequent citations in the text and in the reference list.

If you used the computer-generated HOMA2 index to calculate your results, you should refer to this directly (e.g. https://www.dtu.ox.ac.uk/homacalculator/) and include the date that you accessed the site (day, month, year).

<Back to index>

MINMOD program (insulin sensitivity)

To enable comparison of units for insulin sensitivity index generated by the MINMOD program with results in other papers, we have included a conversion factor to SI units (i.e. to convert values to SI units multiply by 0.167).

of 53

https://www.dtu.ox.ac.uk/homacalculator/


<Back to index>

Molecular weight/mass

Note that molecular weight is the former name for relative molecular mass (Mr), which has no units. Molecular mass is given in kDa. This term has been changed for you.

Normal values (N) for solutions

Please change normal (N) values for solutions to mmol/l.[Give example]

Units (U)/International Units (I/U)

‘IU’ has been changed to the more commonly used ‘U’. Please let me know if the intended meaning has been changed.

For enzyme units use this alternative:

‘IU’ has been changed to the more commonly used ‘U’ for enzyme units. Please let me know if the intended meaning has been changed.

<Back to index>

of 53


PRECLINICAL STUDIES (involving animals, cells or tissue)

Authors are required to follow the NIH guidelines regarding reporting of experimental conditions (http://www.nih.gov/about/reporting-preclinical-research.htm) to facilitate the replication and interpretation of experiments, and these details are included in our preclinical checklist, which is completed at manuscript submission. In line with this, please include the following information in your article.

Statistics

Please include a sentence to state how your data were expressed e.g. ‘Data are expressed as means (SEM)’.

Please provide details of statistical tests used in your analysis, and whether they were one- or two-sided/tailed.

Replicates

Please state how often each experiment was performed and whether the results were substantiated by repetition under a range of conditions. Please ensure it is clear whether measurements were taken from distinct samples or whether the sample was measured repeatedly.

Randomisation

Please state whether the samples were randomised and specify the method of randomisation. Please make it clear if randomisation was not carried out, or was only carried out for some experiments.

Blinding

Please state whether experimenters were blind to group assignment and outcome assessment. Please make it clear if blinding was not carried out, or was only carried out for some experiments.

Inclusion and exclusion criteria

Please state criteria used for exclusion of any data, samples or animals. Include any similar experimental results that were omitted from the reporting for any reason, particularly if the results do not support the main findings of the study. Describe any outcomes or conditions that were measured or used and are not reported in the results section.

Animal strain

Please give the source (supplier’s name, city, state [for USA, Canada, Australia] and country), species, strain, international strain nomenclature, sex, genetic background and age of animals as well as details of housing and husbandry.

of 53

http://www.nih.gov/about/reporting-preclinical-research.htm


Studies involving cell lines [Human or animal cell lines, not donor cells]

Please report the source, authentication and mycoplasma contamination status of cell lines used.

Antibodies

Please report source, characteristics and dilutions of antibodies and how they were validated. Please also include details of buffers used, as well as source, dilutions and buffers used for secondary antibodies. [NB query not needed for antibodies used in flow cytometry. Highlight query for Ed office if unsure]

Resource identifiers

Please ensure you have provided Research Resource Identifiers (RRIDs) and/or unique identifiers (catalogue numbers etc.) for any key resources used in this study, such as transgenic animals, genetic tools, antibodies etc. Please see https://scicrunch.org/resources for more details of RIIDs.

<Back to index>

of 53

https://scicrunch.org/resources


GENES/PROTEINS

Styling: genes vs proteins, human vs mouse genes

Diabetologia distinguishes between gene symbols and protein abbreviations by using italic font for gene symbols and upright font for protein abbreviations. Please note that gene symbols for humans are styled in uppercase italics, whereas those for rats/mice are styled with an initial capital letter and the remaining letters in lowercase italics. Please check your paper carefully to ensure that this distinction has been made correctly.

For example:Human gene: XYZ Rat/mouse gene: Xyz Protein (any species): XYZ

Styling: transgenic mice [add to end of query above, if needed]

In line with this, mouse gene symbol formatting has been used for transgenic mouse models throughout the paper.

Styling: mRNA

mRNA and cDNA should be referred to in italic text using the correct gene symbol.

For example: Xyz mRNA

Styling: western blots

Since western blots are used to measure relative amounts of proteins, protein abbreviations should be used. Please check that the correct styling (upright capitals) has been used throughout.

<Back to index>

Styling: northern blots

Since northern blots are used to measure gene transcription/levels of mRNA, gene symbols should be used. Please check that the correct styling has been used throughout.

<Back to index>

Styling: knockdown studiesWhere siRNA or similar methods are used for knockdown studies, protein formatting is generally used for the molecule knocked down, whereas the oligonucleotide used for the

of 53


knockdown is formatted using the gene symbol. Please check your paper to ensure that this has been done correctly.

For example ‘knockdown of ABC was carried out using Abc siRNA’

[Please note: if gene symbol formatting is used consistently for knockdown, it can be retained, as some authors prefer this format, and as the issue is not clear cut]

Styling: Recombinant Adenovirus

Since recombinant adenoviruses contain genetic material, they should be styled as upright ‘Ad-’, followed by the gene in italic e.g. Ad-AdipoqAn exception is made for green fluorescent protein, for which Diabetologia style is to use lower case for the first letter of the gene i.e. Ad-gfp

Gene symbols and protein abbreviations

As gene symbols are not, strictly-speaking, abbreviations, they do not need to be defined, provided the up-to-date official gene symbol is used. The related protein abbreviations are, however, written in full at first mention of the protein.

Expression of proteins

For clarity, the term ‘expression’ has been replaced by ‘levels’ or ‘content’ in instances where protein levels are being quantified, e.g. western blots.

<Back to index>

Unofficial vs official gene symbol

Diabetologia uses the Entrez Gene site (mouse, rat, human, etc.) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=geneto check gene symbols. Where you have used an unofficial symbol (alias) for the gene, the up-to-date name has been added in parentheses at first mention in the abstract and in the text.

For example: Xyz (also known as Abc)

Keywords: Add unofficial and up-to-date symbols

To aid electronic scanning we have included both the unofficial gene symbol and up-to-date symbol in the keywords (Xyz and Abc).

[Insert symbols for Xyz and Abc]

HLA allele format

of 53

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene


Diabetologia uses the up-to-date formatting guidelines for HLA alleles, as detailed in http://hla.alleles.org/nomenclature/naming.html. Please check that your manuscript complies with this and make any necessary changes.

HLA gene family styling

HLA is not a gene, but a gene family. It is therefore not styled in italics but should be upright. This change has been made for you throughout.

<Back to index>

Gene set analyses

GSEA software (www.broad.mit.edu/gsea). The following references should be cited in addition to the website URL. Please re-number subsequent references in the text and reference list as necessary.

Subramanian A, Tamayo P, Mootha VK et al. (2006) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545-15550. https://doi.org/10.1073/pnas.0506580102. Available from http://www.pnas.org/content/102/43/15545.abstract

Mootha VK, Lindgren CM, Eriksson K-F et al. (2003) PGC-1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267-273. https://doi.org/10.1038/ng1180. Available from http://www.nature.com/ng/journal/v34/n3/abs/ng1180.html

SHEsis software (http://analysis.bio-x.cn/SHEsisMain.htm). The following reference should be cited in addition to the website URL. Please re-number subsequent references in the text and reference list as necessary.

Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97-98. https://doi.org/10.1038/sj.cr.7290272

If the haplotype analysis function is cited, then the following reference should be cited in addition to Shi & He:

Li Z, Zhang Z, He Z et al (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 19(4):519-523. https://doi.org/10.1038/cr.2009.33

PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/). One of the following references should be cited in addition to the website URL (depending on the version used). Please re-number subsequent references in the text and reference list as necessary.

of 53

https://doi.org/10.1038/sj.cr.7290272

http://hla.alleles.org/nomenclature/naming.html


Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015) Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4: 7. doi: 10.1186/s13742-015-0047-8 [PLINK 1.9 and later]

Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81(3):559-575. https://doi.org/10.1086/519795 [earlier versions of PLINK]

Genetic Power Calculator software (http://ibgwww.colorado.edu/~pshaun/gpc/). The following reference should be cited in addition to the website URL. Please re-number subsequent references in the text and reference list as necessary.

Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19(1):149–150

MeV (MultiExperiment Viewer) software (http://mev.tm4.org). The following references should be cited in addition to the website URL. Please re-number subsequent references in the text and reference list as necessary.

Saeed AJ, Bhagabati NK, Braisted JC et al (2006) TM4 microarray software suite. Methods Enzymol 411:134–193. https://doi.org/10.1016/S0076-6879(06)11009-5

Saeed AJ, Sharov V, White J et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34(2):374–378. https://doi.org/10.2144/03342mt01

PCR primers

Please create a table of primers rather than listing them in the Methods, and allow us to publish this as electronic supplementary material (ESM) on our website. Please insert a reference to the electronic supplementary material at relevant places in the text and supply the ESM table as a separate pdf document. Please ensure that the ESM files are cited in numerical order in the text.

<Back to index>

of 53

http://ibgwww.colorado.edu/~pshaun/gpc/


STATISTICS

Statistics (r values)

Please check notation is used correctly:r bivariate correlation coefficientR multivariate correlation coefficientr2 bivariate coefficient of determinationR2 multivariate coefficient of determination[Delete as appropriate, or add all if r/R and r2/R2 both occur]

Statistics (n values)

Please check notation is used correctly:n sample size of subgroupN sample size of whole population

Data expression

Please include a sentence to state how your data were expressed e.g. Data are expressed as means ± SEM

Where you use the term SE, can this be changed to the standard abbreviation SEM (standard error of the mean)?

[Note for copy-editors: if it is clear that the standard error is for another measure other than the mean, e.g. standard error in the rate, the query does not need to be raised.]

If statistical tests were carried out, please make this clear in the text by reporting exact statistical values (e.g. p values). You are not required to categorise these as significant/non-significant.

Statistical tests

Please provide details of statistical tests used in your analysis, and whether they were one- or two-sided/tailed.

Please include details of any assumptions or corrections made, such as tests of normality and adjustment for multiple comparisons

t tests: Please state whether a paired or unpaired t test was used[Copy-editors please note: ‘Independent sample’ t test is an alternative was of saying ‘unpaired’; if it is stated that the samples are independent, there is no need to state ‘unpaired’, and likewise, if samples are stated as being ‘dependent’, it is not necessary to state ‘paired’]

Covariates

of 53


Please provide a description of all covariates tested in your analysis.

Please make sure the descriptions of covariates adjusted for are correct and consistent throughout your paper [e.g. you list XXX as a covariate in the Methods, but not in the footnote to Table XXX] [copy-editors please raise this query if this lists of adjustments/covariates appear to be different in different parts of the text].

Trend/tended to[ONLY INCLUDE IF MANUSCRIPT DOESN’T INCLUDE p for trend (ptrend) or is not discussing trends over time]Use of the terms ‘trend’ or ‘tended to’ is not permitted when discussing data that do not reach the threshold for significance. Instead, please make it clear that the difference reported is not significant, providing statistical values (e.g. p values).

Reporting significance to ****p<0.0001

Journal policy does not generally allow use of the threshold ****p<0.0001. Please change ****p<0.0001 to ***p<0.001 in tables and figures.

[If exact p values are given, or a lower p value threshold is used without using the **** symbol, this is acceptable, as it is more common in certain types of study.]

β Coefficients

I note that you have reported β coefficients in the main text [location] without including the units. Please check whether the units should be included here. Please note that, for standardised β coefficients, the units are not generally given, as these are reported per SD.

[If you are unsure whether this query is appropriate (it is quite complex), please check with the Editorial office].

Interquartile range (given as single number)

Please provide the limits to the interquartile interval (often referred to as [p25–p75] or [Q– Q3]), rather than the IQR as a single number.

Average

Where you use the term ‘average’, please specify if this is mean or median, if appropriate.

<Back to index>

of 53


RANDOMISED CONTROLLED TRIALS

CONSORT guidelines: abstractThank you for completing your CONSORT checklist for abstracts and for including this information in your abstract (see www.consort-statement.org/?o=1001). In line with these guidelines, please could you also add the following information to your abstract:

ORIn line with CONSORT guidelines (http://www.consort-statement.org/?o=1001) on the reporting of randomised controlled trials, please add the following information to your abstract:

[Pick as appropriate]

TitleInclude identification of the study as randomised.

Trial designInclude description of trial design (e.g. parallel, crossover, cluster).

MethodsInclude eligibility criteria for participants and the setting where the data were collected [NB for copy-editor – eligibility criteria can be summarised in the abstract if criteria are long. Should include age range and main criteria]

Include the interventions intended for each group.

Include specific objective or hypothesis.

Include a clearly defined primary outcome for this report.

Include a description of how participants were allocated to interventions and details of allocation concealment, e.g. allocation by central office; sequentially numbered, opaque, sealed envelopes.

State whether or not participants, caregivers, people doing measurements or examinations, or people assessing the outcomes were blinded to group assignment. Avoid use of terms such as ‘single’- and ‘double’-blinded as these terms are not specific.

ResultsInclude the number of participants randomised to each group.

Include the number of participants analysed in each group.

For the primary outcome, include a result for each group and the estimated effect size and its precision.

Include important adverse (or unexpected) effects or side effects.

of 53

http://www.consort-statement.org/?o=1001



ConclusionsInclude general interpretation of the results.

Trial registration

In line with ICMJE guidelines (www.icmje.org/urm_main.html), Diabetologia requires authors to have registered clinical trials in a registry at the time of conception.

Acceptable registries include any registry that is a primary register of the WHO International Clinical Trials Registry Platform (see www.who.int/ictrp/network/primary/en/index.html) or in ClinicalTrials.gov (http://clinicaltrials.gov/)

FundingInclude the source of funding.

For examples of abstracts formatted in this way, see:http://www.consort-statement.org/Media/Default/Downloads/Extensions/CONSORT%20Extension%20for%20Abstracts%20Checklist.pdf

<Back to index>

CONSORT guidelines: flow diagram

In line with CONSORT guidelines (http://www.consort-statement.org/?o=1001) on the reporting of randomised controlled trials, please include a flow diagram as one of the figures showing Enrolment/Allocation/Follow-up/Analysis (for an outline flow diagram see http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Flow%20Diagram.doc).

<Back to index>

Trials mentioned in other types of article

The International Committee of Medical Journal Editors (ICMJE) recommends that the trial registration number of clinical trials should be included at first mention of the trial in the manuscript. Please include relevant trial numbers in the text in line with this.

<Back to index>

of 53

http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Flow%20Diagram.doc

http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Flow%20Diagram.doc


http://www.consort-statement.org/Media/Default/Downloads/Extensions/CONSORT%20Extension%20for%20Abstracts%20Checklist.pdf

http://www.consort-statement.org/Media/Default/Downloads/Extensions/CONSORT%20Extension%20for%20Abstracts%20Checklist.pdf

http://clinicaltrials.gov/

http://www.who.int/ictrp/network/primary/en/index.html

http://www.icmje.org/urm_main.html


MISCELLANEOUS

Unpublished observations/results/data

Please insert the name(s) of the authors linked to the unpublished observations, specifically naming the guarantor or principal investigator, and including other named authors if appropriate. If the guarantor/principal investigator of the study from which the unpublished data are taken is not listed as an author of the present paper, we require their written consent to cite the results. Please email a copy of this confirmation directly to us. Alternatively, you may replace this with a suitable reference (re-numbering subsequent references in the text and in the reference list, and bearing in mind that abstracts can only be included in the references if they are from the current or previous year).

Personal communication

Please add an affiliation(s) for the communicant(s) (e.g. institute, city, country). We require written consent to cite the communication if the communicant is not an author of the present paper. Please email a copy of this confirmation directly to us.

<Back to index>

Animal models of diabetes

Note that animals are used as models of type 1 and 2 diabetes and cannot have type 1 or type 2 diabetes as such. In the title, and at first mention in the abstract and in the text, your wording has been changed to indicate that the animals are used as a model of diabetes, or that experimental diabetes was induced.

Matching [clinical/human studies only]Please give matching criteria for continuous variables, e.g. age ± 2 years, BMI ± 1 kg/m2. If these variables were not actually matched and were simply similar between the groups, then please ensure this is made clear throughout the manuscript.

[Copy-editors note that ‘matching’ is OK to use in relation to ‘propensity score matching’].

Logarithms

Please give details of the base used for logarithmic transformations (for example log10).

Logarithms (ln)

The format ‘ln’ may not be familiar to all readers and has been replaced by loge in line with journal style.

Exponents

Please style exponential numbers as 1.0 × 10−10 rather than 1.0E−10

of 53


ICD-9 and ICD-10

Where you mention ICD-9, the website URL has been added on first mention: (http://www.icd9data.com/2007/Volume1/default.htm)

Where you mention ICD-10, the website URL has been added on first mention: (http://apps.who.int/classifications/icd10/browse/2016/en).

Where you mention ICD-11, the website URL has been added on first mention:(https://icd.who.int/browse11/l-m/en)

Read codesWhere you mention Read codes, the following website URL has been added: (https://digital.nhs.uk/article/1104/Read-Codes).

<Back to index>

Drug names

European Law requires use of the Recommended International Non-proprietary Name (rINN) for medicinal substances (www.pharmaceutical-journal.com/pj-online-law-and-ethics-change-of-drug-names-from-bans-to-rinns/20011496.article). In line with this, the drug name XXX has been changed to YYY.

As glyburide is a US-named drug and may not be familiar to European readers, it has been replaced by ‘… glibenclamide (known as glyburide in the USA and Canada) … ’

Adrenaline/noradrenaline

Adrenaline and noradrenaline are the official names used by EU members, so have been used throughout, with epinephrine/norepinephrine added in parentheses at first mention.

Sacrificed vs killed

In line with the dictionary definitions, ‘sacrificed’ has been changed to ‘killed’ (there was no ritual involved). Another alternative would be ‘euthanised’.

Abstracts in commentaries

You may insert an unstructured abstract if you wish. Note that some readers only have access to abstracts, not the full text, on PubMed.

of 53

http://www.pharmaceutical-journal.com/pj-online-law-and-ethics-change-of-drug-names-from-bans-to-rinns/20011496.article

http://www.pharmaceutical-journal.com/pj-online-law-and-ethics-change-of-drug-names-from-bans-to-rinns/20011496.article

https://digital.nhs.uk/article/1104/Read-Codes

http://apps.who.int/classifications/icd10/browse/2016/en

http://www.icd9data.com/2007/Volume1/default.htm


Abstract data not in main text

The data cited in your abstract appear to be taken directly from the [figures/tables], and are not cited in the main Results section. To make it clearer where the information comes from, please include it at the relevant places in the Results section. When doing this, please make sure that data are reported consistently in the Abstract and Results, and to the same number of decimal places.

qRT-PCR

RT-PCR is a standard abbreviation for ‘reverse transcription PCR’. Please either use the abbreviation qPCR for quantitative real-time PCR or, if the PCR involves reverse transcription, the abbreviation qRT-PCR can be retained but this should be made clear when the abbreviation is first defined.

<Back to index>

of 53


ACKNOWLEDGEMENTS AND AUTHOR DISCLOSURE

Acknowledgements

[Delete as appropriate]

Please include brief affiliations for the people thanked in the Acknowledgements section.

Please provide a brief affiliation (University/Institute/Company/Organisation, town/city, state [for USA, Canada, Australia] and country) for the person that assisted you in the preparation/writing of the manuscript.

Funding

Please include a separate Funding section after your Acknowledgements which details your sources of funding. Please check with your coauthors that all funding sources have been acknowledged, and that all relevant grant numbers are included. Please note that certain funding agencies have specific requirements regarding the acknowledgement of funding.

Where no specific funding was received, please insert the following statement:This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Role of study sponsor or funderThe ICMJE uniform requirements for manuscripts submitted to medical journals state that authors should describe the role of the study sponsor or funding source, if any, in study design; collection, analysis, and interpretation of data; writing the report; and any restrictions regarding the submission of the report for publication, e.g. ‘The sponsor/funder provided editorial assistance only.’, ‘The sponsor/funder was involved in study design and data collection only’

If the sponsor/funder had no such involvement, the authors should state ‘The study sponsor/funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.’

Funding by UK research councils

All papers funded (in full or in part) by one of the UK’s Research Councils, including the [MRC/BBSRC/ESRC/EPSRC/STFC] must comply with the RCUK’s open access policy. Authors of papers to be published in Diabetologia must select Springer’s Open Choice model of publication. The paper will be published under the Creative Commons Attribution (CC BY) license, which lets others modify, build upon and/or distribute the licensed work (including for commercial purposes) as long as the original author is credited.

Funding by the Wellcome Trust

To comply with the Wellcome Trust’s open access policy, authors of Wellcome-funded papers to be published in Diabetologia must select Springer’s Open Choice model of

of 53


publication. The paper will then be published under the Creative Commons Attribution (CC BY) license, which lets others modify, build upon and/or distribute the licensed work (including for commercial purposes) as long as the original author is credited.

Springer Compact agreement

As the corresponding author for the manuscript is based at one of the institutions with a Springer Compact agreement, this article will qualify for free open access under a CC BY licence. See www.springer.com/gp/open-access/springer-open-choice/springer-compact for further details.

[Copy-editors please note that for the majority of Wellcome- or RCUK-funded papers, the Springer Compact agreement also applies, as the corresponding author is based in the UK; this can be added as an additional paragraph below.]

Springer compact – authorship optionsSpringer Compact deals mean that papers can be published with open access at no cost to the authors if the corresponding author/one of the corresponding authors is at an eligible institution (see https://www.springer.com/gp/open-access/springer-open-choice/springer-compact).

One or more of your co-authors is based at an eligible institution but is not listed as the corresponding author on the paper, thus your paper is not currently available for free open access.

You have the following options: 1. Do nothing. You may request open access publication, which will incur an article

processing charge (for fees see https://www.springernature.com/de/open-research/journals-books/journals).

2. If you feel it is appropriate you may add a second corresponding author who is based at an eligible institution. S/he will receive the copyright transfer email and proofs from Springer. (Proofs can be forwarded to another co-author after receipt.) Your paper will then be published with open access at no cost to yourself.

3. If appropriate, change the corresponding author on your paper to the author/one of the authors based at an eligible institution. Your paper will then be published with open access at no cost to yourself.

If you would like to take up options 2 or 3 please include the details of your co-author’s email and correspondence address in your response to the author query form, or in an email to us.

Contribution statement

The requirements of the International Committee of Medical Journal Editors state that authorship credit should be based on:

(1) substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data;(2) drafting the article or revising it critically for important intellectual content;

of 53

https://www.springernature.com/de/open-research/journals-books/journals


and(3) final approval of the version to be published.

Each of these three conditions must be met by each author.

Your contribution statement has been checked, but it is not clear how XXX and XXX meet condition #1 (conception and design, acquisition of data, or analysis and interpretation of data), XXX and XXX meet condition #2 (drafting or revising the article), and XXX and XXX have not approved the final version.

Please could you check your contribution statement and amend as necessary.

[To add if necessary]Please identify in the contribution statement which author is responsible for the integrity of the work as a whole.

GuarantorIn accordance with the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations 2013; http://www.icmje.org/recommendations/), Diabetologia now identifies who is responsible for the integrity of the work as a whole. The guarantor accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please identify the author(s) who is guarantor of this paper by stating at the end of your Contribution Statement e.g. 'XX is responsible for the integrity of the work as a whole' or 'XX is the guarantor of thiswork'.

of 53

http://www.icmje.org/recommendations


Authors’ relationships and activitiesAuthors are responsible for recognising and disclosing relationships and activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, their work. They should acknowledge in this section any industry links and other personal connections.If there are no relevant relationships and activities please insert the following statement: ‘The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.’

I note that [X] is listed in the affiliations as being employed by [Y]. For completeness, please include this in the ‘Authors’ relationships and activities’ statement.

[If author has included standard wording ‘The authors declare that there is no duality of interest associated with this manuscript’, please replace with the wording above and inform them using the wording below]

Authors’ relationships and activitiesThe wording of the duality of interest section has been updated in line with changes to author disclosures in the ICMJE guidelines.

Research data policyDiabetologia strongly encourages authors to make available to readers all datasets on which the conclusions of the paper rely, preferably by depositing datasets in publicly available repositories or as part of the supplementary material (see http://www.diabetologia-journal.org/instructionstoauthors.html#datapolicy). Persistent identifiers (such as DOIs and accession numbers) for relevant datasets must be provided in the paper. Datasets that are assigned digital object identifiers (DOIs) by a data repository may be cited in the reference list. Data citations should include: authors, year, title, repository name, identifier.

Data availabilityPlease include a statement of data availability. This should include information on where data supporting the results reported in the article can be found (including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study), or whether the data are available on request from the authors or if no data are available. For examples of data availability statements, including examples of openly available and restricted access datasets, see www.springernature.com/gp/group/data-policy/data-availability-statements.

<Back to index>

of 53


REFERENCES

Converting EndNote to plain text

To avoid losing changes made to your references during the editing process, please convert your reference list to plain text prior to sending your updated manuscript.

To do this:

1. Click on the EndNote tab in Word.2. Locate the ‘Bibliography’ section3. Click ‘Convert Citations and Bibliography’ 4. Click ‘Convert to Plain Text’

Alternatively, if EndNote is used to update the reference list (for example if a new reference is added) please make sure changes made at copy-editing are transferred manually to the new version.

[IF AUTHOR HAS TO MAKE CHANGES TO REFERENCES]:If EndNote is used to update the reference list (for example if a new reference is added) please make sure changes made at copy-editing are transferred manually to the new version.

Author name/reference mismatch

Reference no. [000] is not by XXX. Please advise.

Abstract out-of-date

Citations to abstracts are only permissible if the abstract was published in 2020 or 2019. Please replace with details of a full published paper. If this is not possible, please cite as ‘unpublished results’ or ‘unpublished data’, listing all the authors and deleting this reference (please remember to renumber the subsequent references in the text and in the list). If the guarantor/principal investigator of the study from which the unpublished data are taken is not listed as an author of the present paper, we require their written consent to cite the results. Please email a copy of this confirmation directly to us.

[Note that out-of-date abstracts are permissible in Systematic Reviews and Meta-Analyses.]

Reference in preparation/submitted

Reference to articles ‘in preparation’ or ‘submitted’ are not permitted. Please delete these from the reference list and change text citations to ‘unpublished results’ or ‘personal communication’ preceded by a list of contributors and their affiliations. Please note that we require written consent to publication from the author of the communication. Please email a copy of this confirmation directly to us.

of 53


<Back to index>

In press

You state that reference no. [000] is ‘in press’. If possible, please provide details (volume number, page range) or the digital object identifier (DOI) number. If the DOI is not yet available, we require written evidence that the paper has been accepted. Please email a copy of this confirmation directly to us.

<Back to index>

Accepted for publication

Reference 000: Has this paper now been accepted for publication? If so, please provide written confirmation of this from the journal concerned.If the paper has not been accepted, the paper should be cited as 'unpublished results' in the text (you will need to re-number subsequent references in the text and in the reference list). Please insert the names of the authors of the unpublished results. For authors that are not listed as authors of the present paper, we require written consent to cite their results. Please email a copy of this confirmation directly to us.

<Back to index>

ePub ahead of print

Please provide the DOI number, or the volume and page numbers if they are now available.

Websites

Please give the date that the site was accessed (day/month/year).

<Back to index>

Cochrane reviews

The reference to a Cochrane review has been amended in line with their recommendations (see www.cochrane.org/index.htm).

of 53

http://www.cochrane.org/index.htm


FIGURESFigure part labelling

[Delete as appropriate]

Journal style does not allow reference to ‘left panel’, ‘right panel’, ‘upper panel’ or ‘lower panel’. As the panels in the figure are clearly labelled, these terms have been deleted from the legend.

To avoid reference to ‘left panel’, ‘right panel’, ‘upper panel’ or ‘lower panel’, in line with journal style, Figure X has been relabelled [please add specific details].

Please change figure citations in the text to ensure that these new figure parts are correctly cited, where appropriate.

Deletion of p values

p values have been deleted from the figure and the information added to the legend.

<Back to index>

Figures not cited in rising order

Figures should be cited in rising order in the text (they appear in the order XXX). Please re-number or re-order figures as appropriate and amend citations in the text if necessary.

Standard statistical notation

Please use standard statistical notation to indicate significance (*p<0.05, **p<0.01, ***p<0.001; usual order for symbols for different comparisons is: *, †, ‡, §, ¶). Standard statistical notation should still be defined in the figure legends for completeness.

Explanation of statistical symbols

Please provide an explanation for the *, ** and *** symbols in the legend. Please note that these symbols are reserved for *p<0.05, **p<0.01, ***p<0.001, respectively. Alternative symbols can be used in the order †, ‡, §, ¶, if needed; # and $ signs should not be used.

[Copy-editors please note: some authors use the system *p≤0.05, **p≤0.01, ***p≤0.001 – this is also OK, and the standard symbols also apply. Please look out for inconsistencies – we quite often see papers that have used both < and ≤ – this should be consistent within a paper.]

Change of statistical symbols

Non-standard symbols to indicate significance have been replaced by standard symbols in the legend and on the figure itself.

of 53


Standard statistical notation is *p<0.05, **p<0.01, ***p<0.001; usual order for symbols for different comparisons is: *, †, ‡, §, ¶; # and $ signs should not be used.

Non-standard statistics (e.g. ***p<0.003)Standard statistical notation is *p<0.05, **p<0.01, ***p<0.001; the following symbols can be used either for different comparisons or for non-standard statistical levels: *, †, ‡, §, ¶; # and $ signs should not be used.

Please used standard statistical notation in preference, as this is clearest, with different symbols for different comparisons if needed, e.g. *p<0.05, **p<0.01, ***p<0.001 vs baseline; †p<0.05, ††p<0.01, †††p<0.001 vs control.

If it is necessary to use a non-standard level, please use an alternative symbol (not *), e.g. †p=0.02.

Reporting significance to ****p<0.0001

Journal policy does not generally allow use of the threshold ****p<0.0001. Please change ****p<0.0001 to ***p<0.001 in tables and figures.

[If exact p values are given, or a lower p value threshold is used without using the **** symbol, this is acceptable, as it is more common in certain types of study.]

p values

Please clarify which variables are being compared.

Graph plotted on logarithmic scale

For figures plotted on a logarithmic scale, please state this in the figure legend, including the logarithmic base used.

Data extending beyond axis

Please amend the y-axis so that the upper and/or lower value exceeds the highest/lowest data points.

Irregular scale

The x-axis is not on a standard scale in that the intervals between the numbers are not regular. Please update the graph so that the intervals are uniform.

High resolution figures

Please supply high resolution versions of your figures:

Line graphs: EPS, AI or PowerPoint vector files if possible, or otherwise TIFF files saved at 1200 dpi

of 53


Micrographs: TIFF files saved at 600 dpi

Composite figures (line graphs and micrographs): EPS, AI or PowerPoint vector files if possible, or otherwise TIFF files saved at 600 dpi

Forest plots

Please provide a new version of your forest plot (Fig. XXX) with the following amendments:

[Choose from list]

Please include ‘et al’ with the author name (or the second author name if there are only two authors).

Please include the year for each study (optional)

Please include reference citation numbers shown in square brackets after the year of the study.

For example:

ADVANCE [23]

Smith et al (2008) [14]

Brown et al (2004) [3]

Individual data points rather than barsColumn scatter graphs rather than bars:

Please convert your bar charts so that they show individual data points on the bars,

or are presented as column scatter graphs, with the mean and error bars shown as lines.

of 53


y-axis values

Please amend the y-axis so that the upper and/or lower value exceed the highest/lowest data points

n values

Please provide exact n values for numbers of samples for each figure part, rather than, for example, n=3–6. [Only need to include this query where the individual data points are not shown, for example in line graphs]

For complex experiments including variable numbers of samples and replicates, consider including this information in a table under the x-axis [add link to styleguide when Fig. Uploaded] e.g.:

For complex experiments including variable numbers of samples and replicates, consider including this information in a table in the ESM and refer to the ESM in the figure legend. [add link to 17 1874 Reddy when online]

of 53


[List end]

Scale bars

Please add scale bars to the micrographs. Please add the bar only to the figure, and give the size in the legend, e.g. ‘Scale bar, 10 μm’.

of 53


Downloadable slide sets (reviews only)

We will produce a downloadable slide set of your figures that will be published with your review as electronic supplementary material (ESM).

<Back to index>

Multimedia manuscripts

Manuscripts containing video material can be published as multimedia manuscripts, and the videos can be embedded in the HTML version of the article, although not in the PDF. The video files would also be included as electronic supplementary material (ESM) so that they are accessible to people downloading the PDF version. This is a new initiative and is an alternative to publishing the video files as ESM only.

Up to three videos per manuscript can be embedded, with the following file requirements: Aspect ratio: 16:9 or 4:3 (please note that this needs to be exact) Maximum file size 25 GB Minimum video duration: 1 sec Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts,

m4v, 3gp Video files should not contain anything that flashes more than three times per second

(so that users prone to seizures caused by such effects are not put at risk)

If you wish your video files to be included in this way, please ensure that these requirements are met, provide a video title/caption, and indicate where in the manuscript the video files should be embedded.

of 53


TABLES

Tables not cited in rising order

Tables should be cited in rising order in the text (they appear in the order XXX). Please re-number or re-order tables as appropriate and amend citations in the text if necessary.

Formatting (gridlines)

Please note that the typesetter will not print internal gridlines. Please make any amendments necessary.

<Back to index>

Formatting (rows of space)

Please note that the typesetter will not print internal rows of space. Please amend as necessary.

Formatting (bold type)

Please note that the typesetter will not print bold in the table. Please amend as necessary, using footnotes if needed, for example to indicate statistical significance. When doing this, please use standard statistical notation (*p<0.05, **p<0.01, ***p<0.001; usual order for symbols for different comparisons is: *, †, ‡, §, ¶) to indicate significance. [NB for copy-editors: this only needs to be raised where bold formatting of data is used to indicate statistical significance or something similar – we don’t need to raise this for bold in headings or other general formatting changes as it can confuse the authors.]

Formatting changes

Some formatting changes have been made to the tables in line with journal style. Cell size and font will be adjusted by the typesetters to ensure optimal presentation.

Large tables

[NB copy-editors: it is generally better to make these suggestions to the authors first rather than doing too much work on reformatting the table yourselves, as the authors may prefer to do things differently.]

Large tables summarising information from different sources can present problems in terms of layout, so it is important to consider how best to set them out before we send them for typesetting.

of 53


Please consider the following ways of reducing the size of your table: - Reword the set-up and findings of the studies you report as brief summaries. This

will also help ensure consistency of wording across the table. For example XXX- Use abbreviations where appropriate, and define them in the table footnotes if they

have not been used elsewhere in the text. Abbreviations that are not generally acceptable in the main text, such as T2D, are allowed in tables, and are encouraged where space is short. For example XXX

- Use footnotes to avoid having to repeat similar information across cells. For example XXX

- For exceptionally wide tables, please consider whether some of the columns could be removed from the version of the table to be published in the main text; the unabridged table could then be published as a supplementary file. For example XXX

Please make sure the entries in your table are ordered in the most appropriate way (e.g. by date order or alphabetically) as it is difficult to change the order of a table at the proof stage.

<Back to index>

of 53


ESM

ESM files

Electronic supplementary material (ESM) will be published online as received without any editorial changes. You are welcome to take this opportunity to revise your ESM in the light of the copy-editor’s changes and queries to ensure that the ESM is consistent with the main text. In particular, please check the following:

[Choose from list]

Gene symbol styling is appropriate for mouse/rat vs human and consistent with main text

Protein abbreviations are correctly styled and consistent with main text SI units are used throughout (e.g. mmol/l for plasma glucose, pmol/l for plasma

insulin, Bq for radiation, etc.) Abbreviations not used and defined in the main text are explained

[List end]

[Choose from list]

Please supply your ESM [any replacement ESM] as a single pdf file, with parts arranged in this order: ESM text (methods and results), tables and figures [and finally lists of study group members, if applicable].

[Certain large tables supplied as Excel files should still be provided separately]

ESM will not undergo any copyediting and will be published online exactly as supplied by the author so please do not include highlighting in your amended version.

Please provide ESM figure legends on the same page as the accompanying figure, where possible, rather than listing them together.

Please ensure that each ESM part contains an identifying header (e.g. ESM Fig. 1).

You may also wish to amend the titles of your ESM sections to be consistent with the citations in the copy-edited text of your paper (e.g. ESM Fig. 1).

Please ensure that the ESM tables and figures are cited in order in the main text (i.e. ESM Table 1 should be cited before ESM Table 2, but call outs to ESM tables can be interspersed with call outs to ESM methods and/or ESM figures.)

If your study included the use of a questionnaire that is not referenced and publicly available, please include the questionnaire as ESM.

Excel files in ESM

of 53


If there is more than one Excel table please provide the tables in the same Excel file, with each table on a separate worksheet within the same file.

Excel files in ESM [raise this query where tables or lists of genes are supplied as Excel files]

Please be aware that Excel software may inadvertently convert gene symbols or other text to dates or numbers (for example the gene symbol SEPT2 could be changed to date format). You may therefore wish to check formatting of cells in your spreadsheet to avoid this problem, or supply tab-delimited files as an alternative. See www.ncbi.nlm.nih.gov/pmc/articles/PMC4994289/ for more information on this.

Moving ESM data to a repository

The Editor has requested that the following data [insert details here] be moved from the electronic supplementary material (ESM) to a separate data repository. This should be cited at an appropriate place in the text, or in your ‘Data availability section’ and should be separate from the numbering of your ESM Tables/Figures. Please renumber the remaining ESM in line with this change.

Duplication of ESM in repository

Please note that datasets published on your own servers or on publicly archived data repositories should not be included with the ESM, and should be cited and numbered separately from the ESM documents, to avoid duplication. The URL to access these documents should be provided in the data availability statement, and in citations in the text if appropriate.

[List end]

<Back to index>

of 53

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994289/


COMMENTS (LETTERS)

Comment title

Please supply a unique title for your comment.

Reply to comment, title

Reply to comment: Please use the title of the comment on your paper as your title, followed by the authors of the comment and ‘[letter]’. For example ‘ … . Reply to White CH, Brown P [Substitute appropriate names] [letter]

<Back to index>

of 53


REVIEWS

Subheadings

Subheadings have been added to break up text/where believed to be appropriate. Please note that these are purely suggestions and may be amended as appropriate.

Figures to illustrator

Your figures and figure legends will be sent to our illustrator to bring them into line with journal style.

However, prior to doing this, please [clarify/check changes made]

Following your response, I will send the figure to our illustrator. Please note that we may request some further changes to your figures following this.

OR

Your figures and figure legends will be sent to our illustrator to bring them into line with journal style. Please note that we may request some further changes to your figures following this.

Permissions (use this version where whole figures have been adapted or reproduced)

Figures/tables taken from previous publications must be accompanied by either a statement (e.g. from RightsLink) giving permission to Diabetologia for reproduction in print and electronic formats, or details of the Creative Commons Attribution (CC BY) licence (which permits sharing and adaptation of another’s work providing the original source is properly cited). Please note that permission is usually required for publication of an adapted figure/table. It is the responsibility of the submitting author to investigate whether permission is needed and to pay any fees associated with obtaining permission. [NOT NEEDED IF AUTHORS HOLD COPY-RIGHT]

Alternative permissions query (use this version if it is less clear whether permission is needed, or only for elements used in a schematic)

Please check whether permission or acknowledgements are required for any part of your figure(s), for example [the images of mice or adipocytes]. Images from medical illustration providers (e.g. Server Medical Art; https://smart.servier.com/) may need to be accompanied by an acknowledgement of the source. Figures/tables taken from other published sources may require permission from the publisher and/or author. Please let us know if you need any more information on this.

Permissions – figures created in BiorenderYou note that the figure(s) was created using Biorender. Please confirm that you have a licence to publish figures created using Biorender.

of 53

https://smart.servier.com/


If you do not currently have a license, there are two choices:

1. You can obtain a license so that you can publish your version of the figure(s). Please note that you would have to pay any costs associated with this (see https://biorender.com/pricing/). Figures created using Biorender should contain the following text in the figure legend: ‘Created in Biorender.com’ If you have permission to publish your figure created in Biorender, please make the following stylistic alterations in line with journal style: XXX

2. You can redraw your figure using a different program.

Permissions – figures from ServierThe following permissions line has been added to your figures, in line with journal requirements: This figure was created using Servier Medical Art (https://smart.servier.com/). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License

Text box

A text box may be included in your review if you so wish. If this is something you think your review would benefit from, please inform me of the section/general topic that you would like the text box to be related to and I will be happy to draft a text box up and send it to you for your approval.

For a text-box example, please see http://link.springer.com/article/10.1007%2Fs00125-016-4106-1

of 53

https://creativecommons.org/licenses/by/3.0/

https://creativecommons.org/licenses/by/3.0/

https://smart.servier.com/

https://biorender.com/pricing/

Author Queries€¦ · Web viewUse these as far as possible for your queries, but you may need to...

Documents

Transcript of Author Queries€¦ · Web viewUse these as far as possible for your queries, but you may need to...